{Reference Type}: Journal Article
{Title}: Evaluation of the levels of salivary paxillin in oral potentially malignant disorders and malignant lesions.
{Author}: Hussine AA;Selim K;Shaker O;Kamal Y;
{Journal}: BMC Oral Health
{Volume}: 24
{Issue}: 1
{Year}: 2024 Jul 24
{Factor}: 3.747
{DOI}: 10.1186/s12903-024-04569-z
{Abstract}: <B>BACKGROUND: </B>The scientific community has been particularly interested in oral squamous cell carcinoma (OSCC) because of the cancer's extremely high incidence and fatality rates worldwide. It has been proposed that paxillin is involved in certain malignancies as an oncogene. Additionally, several investigations have assessed paxillin expression and investigated its function in developing distinct human carcinomas, including squamous cell carcinoma. Furthermore, it was discovered that there is a strong link between paxillin levels and cancer progression and spread.<BR><B>OBJECTIVE: </B>This investigation was carried out to analyze and compare the salivary paxillin levels between oral potentially malignant disorders (OPMDs), OSCC and the healthy controls to assess its potential role as a biomarker of oral cancer aiming for early diagnosis and better prognosis of OSCC.<BR><B>METHODS: </B>Forty-five patients, ranging in age from thirty to seventy-five, were divided into three groups: fifteen patients with OPMDs, fifteen patients with OSCC, and fifteen controls. Paxillin was identified in saliva samples by using an ELISA kit.<BR><B>RESULTS: </B>Patients with OSCC and OPMDs have considerably greater salivary Paxillin levels than the healthy control group. The receiver operating curve (ROC) analysis was used in our study to distinguish patients with OPMDs from those with OSCC. The ROC curve constructed with the OPMDs group as the positives had lower sensitivity and area under the curve (AUC) values [100% and 1] than the ROC curve with the malignant group as the positives [93.3% and 0.997], respectively. Furthermore, ROC analysis performed between OPMDs group and the malignant group showed a specificity of 73.3% and a cut-off value ≥ 7.9 .<BR><B>CONCLUSIONS: </B>Paxillin can be considered a reliable biomarker for identifying and comparing OPMDs and OSCC cancerous changes.<BR><B>RESULTS: </B><BR><B>UNASSIGNED: </B>NCT06154551- 4/12/2023.